Skip to main content

Esophageal Cancer Clinical Trials

Review the esophageal cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 51-75 of 152

Propranolol and Chemoradiation Therapy for the Treatment of Patients with Esophageal Cancer
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Preoperative Hypofractionated Radiotherapy with FOLFOX for the Treatment of Stage I-III Esophageal or Gastroesophageal Junction Adenocarcinoma
Status: Active
Location: 2 locations
Neratinib in Combination with Chemotherapy, Trastuzumab, Pembrolizumab in Patients with Stage HER2 Overexpressing Stage IV Gastroesophageal Cancers
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Chemotherapy with or without Radiation or Surgery in Treating Participants with Oligometastatic Esophageal or Gastric Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Propranolol in Combination with Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Ivonescimab in Combination with a Standard Chemotherapy Regimen (FOLFOX) for Controlling Disease Progression in Patients with HER2 Negative Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Tucatinib Given Before Surgery to Patients with HER2 positive Cancers that have Spread to the Brain
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
Status: Active
Location: University of California San Francisco, San Francisco, California
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cabozantinib and Durvalumab with or without Tremelimumab in Treating Patients with Stage III-IV Gastroesophageal Cancer and Other Gastrointestinal Malignancies
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Status: Active
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Status: Active
Location: Wayne State University/Karmanos Cancer Institute, Detroit, Michigan
[18F]FMISO PET/CT/MRI Informed Radiation Therapy for the Treatment of Esophageal Cancer, PIONEER Study
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Personalized Cancer Vaccine for the Treatment of Muscle-Invasive Bladder Cancer and Gastroesophageal Cancer in Patients with Molecular Residual Disease
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
Status: Active
Location: 2 locations
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Status: Active
Location: 2 locations
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Status: Active
Location: 2 locations
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
Status: Active
Location: Northwestern University, Chicago, Illinois
FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of MGC026 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas